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Polarized cells such as neurons and endothelial cells
appear to be involved in two invariant pathological fea-
tures of Alzheimer’s disease pathology, namely the for-
mation of senile plaques and cerebral amyloid angiopa-
thy. This implicates polarized sorting mechanisms in
the production and accumulation of amyloid -peptide
(A). We have now studied polarized sorting of -secre-
tase (BACE) in Madin-Darby canine kidney (MDCK)
cells. The majority of BACE is sorted to the apical sur-
face of MDCK cells where very little -amyloid precur-
sor protein (APP) is observed, because APP under-
goes basolateral sorting. Consistent with the usage of
similar mechanisms for polarized sorting, BACE was
also found to be targeted to axons of hippocampal neu-
rons. The remaining basolaterally sorted BACE com-
petes with the highly polarized basolateral -secretase
activity. Therefore, substantial amounts of BACE are
targeted away from APP to a non-amyloidogenic com-
partment, a cellular mechanism that limits A genera-
tion. In addition, no -secretase activity was observed
on the apical side whereas -secretase activity is ob-
served on the basolateral and the apical side. Consistent
with this finding, substantial amounts of A can be pro-
duced apically upon missorting of APP to the apical
surface. These data demonstrate that A production is
limited in polarized cells by differential targeting of
BACE and its substrate APP. Moreover, our findings
suggest that APP may not be a major physiological
substrate of BACE.
Proteolytic enzymes called secretases play a pivotal role in
the generation of amyloid -peptide (A1), the major compo-
nent of the Alzheimer’s disease (AD)-defining senile plaques
and microvascular deposits (1). -Secretase (BACE), a mem-
brane-bound aspartyl protease (2–6), is responsible for the
cleavage at the N terminus of the A domain at Asp-1 and
Glu-11. This heterogenous cleavage results in the generation of
membrane-bound APP C-terminal fragments (APP CTFs),
which are the immediate precursors for A generation (1), and
in the secretion of the truncated ectodomain of APP (7).
-Secretase activity, which critically requires the presenilins
PS1/PS2 (8–15), mediates the cleavage at the C terminus of the
A domain. This final proteolytic event results in the secretion
of A into biological fluids (1) and the liberation of the C-
terminal domain of APP into the cytoplasm (16). A third
secretase, the -secretase, prevents A generation by cleaving
in the middle of the A-domain. The -secretase activity is
associated with three members (ADAM 9, 10, and 17) of the
ADAM (a disintegrin and metalloprotease) family (17–19) and
generates the secreted ectodomain of APP (APPs). The re-
maining C-terminal stub is processed by -secretase, which
results in the secretion of p3 (1).
Polarized cells are intimately associated with two invariant
pathological features of AD pathology, namely the formation of
senile plaques and the cerebral amyloid angiopathy. This sug-
gests that polarized sorting mechanisms may be involved in the
production and accumulation of A. As a model system to study
polarized sorting of APP and the three secretase activities, we
used the well characterized Madin-Darby canine kidney
(MDCK) cells, because they allow the generation of stably
transfected cell lines with moderate expression levels and ap-
pear to use similar mechanisms for polarized sorting as neuro-
nal cells (20). Moreover, experiments on polarized sorting of
APP in this cell line provided first evidence for the cellular
mechanism underlying the enhanced A production caused by
the Swedish mutation (21, 22), thus demonstrating the rele-
vance of MDCK cells for studies on APP processing. APP is
known to undergo polarized sorting in MDCK cells (21–24) as
well as in neurons (25, 26). In MDCK cells the APP holopro-
tein and its proteolytic products are predominantly targeted to
the basolateral side. A targeting signal containing a tyrosine
within the cytoplasmic domain of APP is required for polar-
ized sorting of membrane-associated APP (24). Deletion of the
cytoplasmic sorting signal of APP leads to an equal surface
distribution of membrane-associated APP, whereas APPs
continues to be secreted predominantly from the basolateral
surface (24). Moreover, expressing the familial AD-associated
Swedish mutation, which is known to enhance BACE-mediated
APP processing (27, 28), reveals apical secretion of Swedish-
APPs (21, 22).
Understanding the cellular sorting pathways associated
with proteolytic processing of APP and, specifically, the mech-
anisms that allow the secretase activities to come into contact
with their substrate APP will help reveal and prevent amy-
loidogenesis. We therefore analyzed the sorting of BACE and
its enzymatic activity in terms of A production in polarized
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cells. Parallel investigation of the - and -secretase activity
revealed differential sorting of the two amyloidogenic secreta-
ses and their substrate APP. This sorting mechanism appar-
ently limits A production, by allowing efficient competition of
the exclusive basolateral -secretase activity with the low
amounts of basolaterally sorted BACE.
EXPERIMENTAL PROCEDURES
cDNA Constructs—cDNA constructs encoding BACE were amplified
by PCR and subcloned into the EcoRI/XhoI site of the pcDNA3.1/zeo()
expression vector (Invitrogen) as described previously (29).
Tissue Culture—MDCK cells (strain II) were maintained in Dulbec-
co’s modified Eagle’s medium supplemented with 10% fetal bovine
serum and antibiotics. All stable transfections of MDCK cells were
performed with FuGENE (Roche Diagnostics) as described by the man-
ufacturer. Cell lines expressing BACE or presenilin constructs from
pcDNA3.1/Zeo were selected with 400 g ml1 zeocin. Cell lines with
moderate expression levels and normal morphology were selected for
the study. To obtain polarized monolayers for surface biotinylation or
metabolic labeling, cells were plated at confluence on 24-mm polycar-
bonate Transwell filter (Corning Costar Corp.). For immunocytochem-
istry cells were plated on a 12-mm diameter filter. Media were changed
each day, and cells were used for the corresponding experiment after
5–6 days. To increase expression levels cells were treated overnight
with 10 mM butyrate. Similar results were obtained with untreated and
treated cells.
Primary cultures of hippocampal neurons were prepared and cul-
tured according to standard conditions.
Antibodies—The polyclonal antibodies 7523 and GM190 directed to
the N terminus (amino acids 46–60) and the pro-peptide (amino acids
22–45) of BACE were described previously (29). The polyclonal anti-
body 3027 against the large loop of PS1 and the monoclonal antibody
PS1N against the N terminus of PS1 were described previously (30).
Immunocytochemistry and Confocal Imaging—Cells grown on filters
were washed with PBS containing 1 mM CaCl2, 0.5 mM MgCl2 (PBS
).
Antibody 7523 (1:100 in 0.2% BSA/PBS) was added to the apical or
basolateral surface for 30 min at 4 °C. After extensive washing in PBS,
cells were fixed in 4% paraformaldehyde/PBS for 30 min at 4 °C,
quenched for 10 min in 50 mM NH4Cl/PBS
, and then incubated with
the fluorochrome-conjugated secondary antibody (Alexa 488, Molecular
Probes, 1:250) for 45 min at 37 °C. After extensive washing, filters were
cut out and mounted in Moviol. Confocal images were obtained with a
Leica TCS SP confocal laser scanning microscope (Leica Microsystems)
equipped with an oil immersion plan-apochromatic 100/1.4 numerical
aperture objective lens. Fluorochromes were visualized using an argon
laser with excitation wavelengths of 488 nm, emission filter 490–530
nm (for Alexa 488). Images were recorded with 512-  512-pixel reso-
lution and processed with Photoshop version 5.5 (Adobe Systems, Inc.).
Hippocampal neurons were transfected with an endotoxin-free BACE
cDNA using Effectene (Qiagen). 36 h after transfection, neurons were
fixed and stained with the affinity-purified antibody 7523 and costained
with a monoclonal anti-MAP-2 antibody.
Metabolic Labeling and Immunoprecipitation—For pulse-chase ex-
periments, MDCK cells grown on Transwell filters were starved for 45
min in methionine- and serum-free minimal essential medium and
subsequently metabolically labeled with 300 Ci of [35S]methionine/
[35S]cysteine (Promix, Amersham Biosciences, Inc.) in methionine- and
serum-free minimal essential medium for 10 min and chased in the
presence of excess amounts of unlabeled methionine for the indicated
time points. Cells were lysed in buffer containing 1% Nonidet P-40 on
ice for 30 min and scraped from the filter, and lysates were clarified by
centrifugation for 20 min at 14,000  g. Immunoprecipitation and
separation by SDS-PAGE was performed as described previously (29).
For the immunoprecipitation of APPs and A, cells were metabolically
labeled for 4 h using 300 Ci of Promix in methionine-free media
containing 5% dialyzed serum. Media collected from the apical and
basolateral chamber were immunoprecipitated. Quantitation was per-
formed by phosphorimaging (PhosphorImager, Molecular Dynamics).
Surface Biotinylation—MDCK cells were grown on filters for 5 days.
The monolayer was washed three times with cold PBS, followed by
incubation with sulfo-NHS-LC-biotin (1 mg/ml, Pierce) either apically
or basolaterally for 1 h at 4 °C. 1% BSA in PBS was added to the
opposite chamber. The reaction was stopped by washing with PBS and
quenched with 10 mM glycine, 1% BSA in PBS. Cell lysates were
prepared and precipitated with streptavidin-Sepharose (Amersham
Biosciences, Inc.). The precipitated, biotinylated proteins were sepa-
rated on SDS gels and transferred to polyvinylidene difluoride mem-
branes. For detection of BACE, PS1, or APP, the indicated antibody
was used. Specifically bound antibodies were visualized by a horserad-
ish peroxidase-conjugated secondary antibody using the enhanced
chemiluminescence technique (Amersham Biosciences, Inc.) or an 125I-
conjugated secondary antibody.
Enzymatic Deglycosylation—These experiments were done as de-
scribed previously (29).
Fluorometric BACE Activity Assay—A quenched fluorescence sub-
strate Cy3-SEVNLDAEFK(Cy5Q)-NH2 containing the Swedish APP
mutation (in boldface) and a non-cleavable substrate Cy3-
SEVKVDAEFK(Cy5Q)-NH2, containing an amino acid exchange, M 3
FIG. 1. Expression and maturation of functionally active
BACE in MDCK cells. A, maturation of BACE in MDCK cells. Left
panel, MDCK cells stably expressing BACE were pulse-labeled with
[35S]methionine/cysteine and chased for the indicated time points in the
presence of excess amounts of unlabeled methionine. Cell lysates were
immunoprecipitated with antibody 7523. Note that antibody 7523 pref-
erentially detects mature BACE (29). Right panel, N-glycosylation and
oligosaccharide modification of BACE. MDCK cells stably expressing
BACE were pulse-labeled with [35S]methionine and chased in the pres-
ence of excess amounts of unlabeled methionine for 2 h. Cell lysates
were immunoprecipitated with antibody 7523 and treated with () and
without () endoglycosidase H. Note that the mature form of BACE is
endoglycosidase H-resistant. B, membranes from BACE-transfected
() or untransfected MDCK cells (Œ) were solubilized and analyzed in
vitro for proteolytic activity. Incubation of the fluorogenic peptide con-
taining the Swedish mutation with solubilized membrane fractions
from BACE-transfected () MDCK cells allowed a significant time-de-
pendent proteolytic reaction, whereas the non-cleavable substrate pep-
tide with the Met to Val mutation at the P1 side is not proteolyzed (X).
Moreover, incubation with the BACE-specific inhibitor GL189 (5 M)
blocked the proteolytic activity of solubilized membrane fractions from
BACE-transfected cells (●). Untransfected MDCK cells show very little
BACE activity (Œ), which appears to be below the detection limit of the
in vitro assay. Substrate peptides and the BACE-specific inhibitor
GL189 are shown below. The NL mutation (Swedish mutant substrate)
as well as the V mutation (non-cleavable control substrate) are shown in
red.
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V (in boldface) were synthesized by Amersham Biosciences, Inc., UK.
Membranes from BACE-transfected and non-transfected MDCK cells
were prepared and extracted with 1% Triton X-100, 20 mM MES, pH
6.0, including a protease inhibitor mix (Sigma Chemical Co.). The assay
was carried out in a volume of 200 l containing 400 nM peptide
substrate or the non-cleavable control peptide, 2 l of the membrane
preparation, and 20 mM sodium acetate, pH 4.4. Fluorescence was
measured continuously over a period of 15 min, at room temperature
(Fluoroskan Ascent, Labsystems, Finland, excitation 530 nm, emission
590 nm). The -secretase inhibitor (GL189) H-EVNstatineVAEF-NH2
was synthesized by K. Maskos and W. Bode.
Radiosequencing—A peptides were radiosequenced as described
previously (31).
RESULTS
Maturation and Enzymatic Activity of BACE in MDCK
Cells—BACE mediates the initial amyloidogenic cleavage,
which produces the direct precursor for A production. Due to
the pivotal importance of this cleavage, we first investigated
BACE maturation and its proteolytic activity in MDCK cells.
Because endogenous levels of BACE are too low to allow its
direct biochemical and cellular analysis (2), we stably trans-
fected MDCK cells as well as a previously described MDCK cell
line (23) overexpressing human wt APP with a BACE cDNA
expression construct. In addition to overexpressed BACE, we
also monitored the distribution of endogenous BACE activity
by analyzing its primary cleavage product APPs (see below).
MDCK cells stably expressing human BACE were analyzed in
pulse-chase experiments for maturation and glycosylation of
BACE. After a short pulse, immature BACE is detected by
immunoprecipitation of cell lysates with antibody 7523 (29)
(Fig. 1A). Over time, efficient maturation to a higher molecular
weight variant was observed (Fig. 1A), which lacks the pro-
peptide (data not shown). The fully glycosylated high molecular
weight BACE variant reaches a post-Golgi compartment as
demonstrated by the selective resistance of this variant against
endoglycosidase H (Fig. 1A). We next investigated whether
overexpressed BACE is catalytically active in MDCK cells.
Membranes were prepared from BACE-transfected and un-
transfected MDCK cell lines. Solubilized membrane fractions
were incubated with a fluorogenic APP-derived peptide ex-
tending from P5 to P5 containing the Swedish mutation (Fig.
1B). This peptide contains one of the two known cleavage sites
of BACE (see below). Compared with membrane extracts from
untransfected cells, a high proteolytic activity is present in
extracts derived from a BACE-transfected cell line (Fig. 1B).
When solubilized membranes of BACE-transfected cells were
incubated with the BACE inhibitor GL189 (Fig. 1B), a complete
inhibition of the proteolytic activity was observed (Fig. 1B).
Finally, we used a peptide, which contained a Met to Val
substitution at the P1 site (Fig. 1B). This mutation was previ-
ously shown to inhibit endoproteolytic cleavage by BACE (2,
32). Consistent with these observations, the mutant peptide
was not proteolyzed in the in vitro assay containing solubilized
membrane fractions from BACE-transfected cells (Fig. 1B).
These results thus demonstrate that fully mature biologically
active BACE with its expected biochemical features is ex-
pressed in MDCK cells. In addition to the cleavage at the
critical Asp-1 of the A domain, we also detected significant
cleavage activity at Glu-11 (see below), which is consistent with
previous reports (2, 33–36) and represents another major in
vivo cleavage site of BACE.
Surface Distribution of BACE—To determine the surface
distribution of BACE, the MDCK cell lines described above
were grown on Transwell filters to form polarized monolayers.
These were incubated with antibody 7523 to the ectodomain of
BACE on the apical or basolateral surface. Laser confocal mi-
croscopy revealed BACE expression on each surface (Fig. 2A).
This was further confirmed by analyzing vertical cross-section
(z axis) of polarized monolayers (Fig. 2A, lower panel).
Cell surface targeting of BACE was analyzed by direct bio-
tinylation of mature BACE at the plasma membrane. Three
individual MDCK cell lines, which express different levels of
BACE, were selected (Fig. 2B). In addition to two high express-
ing lines (lines 8 and 41) a low expressing line (line 14) was
chosen to avoid saturation of polarized sorting. Polarized mono-
layers were chilled to 4 °C and labeled with sulfo-NHS-LC-
biotin on the basolateral or the apical side. After lysis, biotiny-
FIG. 2. Sorting of BACE in polarized MDCK cells and rat hippocampal neurons. A, immunocytochemical detection of BACE. Monolayers
of MDCK cells stably expressing BACE were incubated with antibody 7523 on the basolateral or apical side. Bound antibodies were detected with
a secondary fluorescent antibody. Note the detection of BACE on either side of the monolayer. Lower panel, vertical cross-sections (z axis).
Basolateral and apical BACE are indicated by the arrowheads. Bar, 10 M. B, expression and cell surface distribution of BACE. Three independent
cell lines expressing low or high levels of BACE were analyzed (detected by immunoblotting with antibody 7523; upper panel). Lower panel, cell
surface biotinylation of BACE. Biotinylated surface proteins were isolated using streptavidin-coated Sepharose. Surface-biotinylated BACE
molecules were detected by immunoblotting using antibody 7523 and quantitated. Data shown are average  S.D. of three independent
experiments. C, axonal targeting of BACE in hippocampal neurons. 36 h after transfection of fully differentiated neurons with the human BACE
cDNAs, neurons were fixed, permeabilized, and costained with the affinity-purified antibody 7523 (BACE) and a monoclonal anti-MAP-2 antibody
(MAP-2) to label the somato-dendritic compartment. The merged image (merge) demonstrates axonal (white arrowheads) and somato-dendritic
sorting of human BACE.
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lated surface proteins were isolated using streptavidin-coated
Sepharose. Surface-biotinylated BACE molecules were de-
tected by immunoblotting using antibody 7523. This revealed
that the mature BACE variant is exclusively targeted to both
cell surfaces (Fig. 2B). No pro-peptide-containing immature
BACE was detected on the cell surface (data not shown). Quan-
titation of multiple experiments with three independent indi-
vidual cell lines revealed that 70–80% of BACE are targeted
to the apical surface, whereas only about 20–30% were found
on the basolateral surface (Fig. 2B) where most of the APP
substrate is located (23). The low expressing line showed the
most efficient apical targeting of BACE (Fig. 2B) indicating
that apical sorting of BACE can be affected by very high ex-
pression levels.
The sorting of BACE to the apical compartment together
with about 20–30% basolateral targeting suggests that BACE
is expressed in neurons in axons as well as in the somato-
dendritic compartment (20). To prove this, fully differentiated
rat hippocampal neurons were transfected with a BACE cDNA.
Cells were costained with antibody 7523 to BACE and with an
anti-MAP2 antibody to specifically identify somato-dendritic
compartments. As shown in Fig. 2C, BACE is indeed targeted
to both axons and somato-dendritic compartments.
Basolaterally Sorted BACE and -Secretase Compete for
APP—We next investigated the polarized distribution of -
and -secretase products in MDCK cell lines, which overex-
press either human APP alone or together with BACE. Ali-
quots of conditioned media from metabolically labeled cells
were immunoprecipitated with the neo-epitope-specific anti-
body 1736 (Fig. 3A) (37), which specifically detects -secretase-
generated soluble APPs. As reported previously (24), cells
expressing only APP secreted APPs basolaterally (Fig. 3B).
In contrast, the additional expression of BACE resulted in very
low levels of APPs secretion (Fig. 3B). In fact, basolateral
secretion of APPs was selectively reduced (Fig. 3B). This
suggests that overexpressed BACE is competing with endoge-
nous -secretase within the basolateral targeting pathway,
thus producing APPs (which is not detected by antibody 1736)
to the expense of APPs.
To determine the amounts of APPs produced by BACE, we
immunoprecipitated secreted APPs species with antibody 5313
(38), which allows detection of both APPs and APPs (Fig.
3A), and compared the immunoprecipitated species with
APPs isolated with antibody 1736 (Fig. 3A). In clear contrast
to antibody 1736 (Fig. 3B), antibody 5313 detected robust levels
of secreted APPs in both compartments of MDCK cells overex-
pressing BACE and APP (Fig. 3C). These migrated to a
slightly lower molecular weight consistent with BACE-gener-
ated truncated APPs (27, 28). Moreover, quantitation (by cal-
culating the difference between total APPs precipitated by
antibody 5313 and APPs isolated by antibody 1736) revealed
equal secretion of APPs into the apical and basolateral com-
partments of double-transfected cells (Fig. 3D). This result
demonstrates that APPs can be secreted at both surfaces (Fig.
3, C and D), whereas APPs is almost exclusively secreted from
the basolateral side (Fig. 3B). This is supported by the finding
that APPs is also secreted into the apical and basolateral
compartment by cells not transfected with BACE (Fig. 3, C and
D). However, the significant increase of total APPs secretion
into the basolateral and apical compartments upon BACE over-
expression indicates cleavage of APP before it reaches the
sorting compartment within the trans-Golgi (see “Discussion”).
Apically Missorted APP Is Efficiently Proteolyzed by BACE
and -Secretase—The above described results suggest a high
endogenous BACE activity on the apical side, where it can
produce APPs in equal amounts as on the basolateral side,
although only about 10% of the APP holoprotein is targeted to
the apical side. This indicates a very efficient BACE-mediated
processing of apically sorted APP probably due to the lack of
apical -secretase activity. To prove this, we expressed a C-
terminally truncated APP derivative (APPC), which we
have shown previously to be targeted to both surfaces due to
the loss of the cytoplasmic sorting signal (24). Aliquots of con-
ditioned media from metabolically labeled MDCK cells express-
ing APPC were immunoprecipitated with neo-epitope-spe-
cific antibody 1736 or with antibody 5313. As shown before (24),
APPs is almost exclusively secreted into the basolateral com-
partment, independently of the sorting of the APP holoprotein
(Fig. 4). In contrast, a significant increase of APPs secretion
FIG. 3. Polarized secretion of APPs and APPs. A, schematic
representation of APP. The sites of secretase cleavages (arrows) and
epitopes used for immunization (bars) are indicated. B, polarized secre-
tion of APPs. Conditioned media of MDCK cells stably transfected
with APP and BACE, or APP alone were immunoprecipitated with
antibody 1736 to exclusively identify APPs. Lower panel, quantitation
of the amounts of APPs secreted on either side of the polarized mono-
layer. Data shown are average  S.D. of three independent experi-
ments. C, polarized secretion of total APPs (APPs and APPs). Con-
ditioned media of MDCK cells transfected with APP and BACE, or
APP alone were immunoprecipitated with antibody 5313 to identify
APPs and APPs. Antibody 5313 detects higher levels of APPs within
the basolateral than in the apical compartment of cells expressing only
APP. This is due to the fact that these cells also secrete high levels of
APPs (compare immunoprecipitations with antibody 1736 in B). Lower
panel, quantitation of the amounts of total APPs secreted on either side
of the polarized monolayer. Data shown are average  S.D. of three
independent experiments. D, quantitation of the amounts of APPs
secreted on either side of the polarized monolayer. The amounts of
APPs were determined by calculating the difference of total APPs and
APPs. Data shown are average  S.D. of three independent experi-
ments. Note that both antibodies have similar affinities to APPs (data
not shown).
Sorting of -Secretase Limits A Production5640










into the apical compartment is observed (Fig. 4). Therefore,
apically sorted full-length APP is almost exclusively cleaved
by BACE, whereas basolateral APP appears to be processed
by - and -secretase in a competitive manner. It is important
to note that the distribution of endogenous BACE activity in
the presence of mistargeted APP reflects the distribution of
cell-surface biotinylated BACE (compare Fig. 4 with Fig. 2)
thus indicating apical sorting of endogenous BACE similar to
that of overexpressed BACE. To further prove this, we next
compared polarized A and p3 secretion in MDCK cells over-
expressing APP/BACE or APP alone. Conditioned media
from the apical and basolateral compartment were immuno-
precipitated with antibody 3926 (39) (Fig. 5A). In cells express-
ing APP alone, A and p3 were almost exclusively secreted
into the basolateral compartment (Fig. 5A). In cells expressing
both APP and BACE, no p3 was detected (Fig. 5A), consistent
with the competitive reduction of -secretory processing, de-
scribed above (Fig. 3B). Instead, high levels of an A species
migrating between native A and p3 were observed in the
double-transfected cells (Fig. 5A). Radiosequencing of this pep-
tide revealed that its N terminus begins predominantly at
Glu-11 (Fig. 5B). Cleavage at Glu-11 is a typical feature of the
-secretase activity and is observed in cells expressing endog-
enous (see below) (31) and overexpressed BACE (2, 33–36). The
truncated A species is secreted only basolaterally, although
the corresponding APPs is equally secreted into the apical and
basolateral compartment (see Fig. 3D). The reason might be
that the precursor of A, the BACE-generated APP CTF, still
contains the sorting signal for basolateral transport (see Fig.
5D for further evidence). We next investigated if a similar
truncated A species could be produced on the apical side,
where high levels of BACE, but little, if any, -secretase activ-
ity was observed. To do so, APPC was expressed, which
allows the trafficking of significant amounts of the APP holo-
protein to the apical side (24). In contrast to the basolateral
secretion of A/p3 in wt APP-expressing cells, overexpression
of the C-terminally truncated APP derivative revealed A
secretion from both surfaces (Fig. 5C). Indeed, high levels of a
truncated A species were observed on the apical side. Due to
the preferentially apical distribution of BACE and the compe-
tition of BACE with -secretase on the opposite side, smaller
amounts of A were detected basolaterally (Fig. 5C). Moreover,
consistent with the above described basolateral activity of
-secretase (Figs. 3B and 4) p3 was exclusively observed in the
basolateral compartment (Fig. 5C). Efficient A production on
the apical site again supports the notion that endogenous
BACE undergoes predominantly apical targeting like the over-
expressed enzyme. This also demonstrates that the Glu-11
FIG. 4. Missorting of APP differentially affects processing by
- and -secretase. MDCK cells overexpressing APPC were meta-
bolically labeled and conditioned media were immunoprecipitated with
antibody 1736 or antibody 5313. APPs and APPs secretion was quan-
titated as described above.
FIG. 5. Apical BACE and -secretase activity. A, polarized distri-
bution of A and p3 in cells expressing APP alone or APP and BACE.
Conditioned media was immunoprecipitated with antibody 3926 (39).
Note the enhanced production of a truncated A species in cells double-
transfected with APP and BACE (arrow). B, radiosequencing of A
secreted from BACE-expressing cells. Cells were metabolically labeled
with [3H]Phe, and A was isolated from conditioned media by immu-
noprecipitation with antibody 3926. The peak of radioactivity in cycles
9 and 10 demonstrates that the N terminus of this A species begins at
Glu-11. C, polarized distribution of A and p3 in cells expressing
APPC. Conditioned media were immunoprecipitated with antibody
3926. Note that A peptides are secreted on both sides, whereas p3 is
exclusively observed within the basolateral compartment. Consistent
with previous findings, increased levels of p3 are found upon deletion of
the APP cytoplasmic domain (24). A truncated A species (most likely
starting at Glu-11; see above) is found predominantly on the apical side
(arrow). D, detection of APP CTFs on the basolateral cell surface.
Biotinylated surface proteins were isolated using streptavidin-coated
Sepharose. Surface-biotinylated APP CTFs were detected by immuno-
blotting using antibody 6687. As shown by the direct immunoprecipi-
tation with antibody 6687, the -secretase-generated APP CTF is very
abundant in MDCK cells, whereas only very small amounts of -secre-
tase generated APP CTFs where observed.
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cleavage can also be observed in the absence of BACE overex-
pression. Moreover, it also demonstrates that significant levels
of -secretase activity must undergo apical sorting.
The exclusive basolateral secretion of A in cells expressing
the wild type APP holoprotein might be due to a basolateral
sorting of the immediate -secretase substrates and may thus
not necessarily reflect the distribution of the -secretase activ-
ity. If that is the case, the APP CTFs generated by - and
-secretase (which are the substrate for -secretase) should be
observed on the basolateral plasma membrane, because these
fragments still contain the required targeting information
within their cytoplasmic tails (24). We therefore investigated
the distribution of such fragments in MDCK cells overexpress-
ing APP alone. Surface-biotinylated APP fragments were
precipitated with streptavidin beads and detected by immuno-
blotting using antibody 6687 (38). This indeed revealed the
presence of APP CTFs predominantly on the basolateral sur-
face (Fig. 5D), thus demonstrating a highly polarized distribu-
tion of these immediate precursors for amyloidogenesis.
From these results we conclude that amyloidogenic process-
ing of APP by BACE is determined by the differential distri-
bution of the -secretase activity and its substrate APP. Due
to the lower levels of basolateral BACE and the competition of
BACE and -secretase for basolaterally sorted APP, A pro-
duction is limited. Moreover, in contrast to the basolateral
sorting of APP, -secretase activity is also efficiently sorted to
the apical side.
DISCUSSION
Based on the results described above the following picture of
polarized APP processing and its interaction with the secre-
tase activities is emerging (Fig. 6). Membrane-bound full-
length APP is targeted predominantly to the basolateral cell
surface. In contrast to its substrate, BACE is sorted preferen-
tially to the apical surface. This is observed upon overexpres-
sion, however, endogenous BACE activity also undergoes sim-
ilar sorting. The - and -secretase-generated APP CTFs,
which are the immediate precursors for the -secretase cleav-
age to produce A and p3 (1), are targeted to the basolateral
membrane, because they contain their cytoplasmic basolateral
sorting signal. At the basolateral membrane or close to it the
final -secretase cleavage takes place, which liberates either
A or p3 (Fig. 6). In contrast, -secretase activity is sorted to
both cell surfaces. Consequently, APP can be a substrate for
-secretase at or close to both surfaces. This does not necessar-
ily imply that PSs are also targeted to both surfaces, because
PSs do not overlap with APP in late secretory compartments,
a phenomenon described as the spatial paradox (40). -Secre-
tase activity is located on the basolateral side, because its
products p3 as well as APPs are both almost exclusively
detected within the basolateral compartment (Fig. 6). Thus -
and -secretase can compete for their substrates only on the
basolateral sorting pathway, a cellular mechanism that appar-
ently determines the levels of A generation in polarized cells.
Basolateral sorting of -secretase activity explains the pre-
vious paradoxical finding on the sorting of APP upon the
deletion of its cytoplasmic sorting signal. Under these condi-
tions the holoprotein is targeted to both surfaces, although
APPs continues to be secreted basolateral (24). Our findings
demonstrate that this is due to the predominantly basolateral
activity of -secretase, which consequently supports preferen-
tial basolateral secretion of APPs and p3 even if half of the
APP molecules are mistargeted to the apical surface.
In contrast to APPs, APPs is secreted from both surfaces
in almost equal amounts. However, as described above only
small amounts of APP reach the apical surface, whereas the
majority is targeted to the basolateral side. The equal amounts
of secreted APPs on the apical and basolateral side of MDCK
cells expressing endogenous BACE are due to cellular mecha-
nisms, which support BACE-mediated cleavage on the way to
the apical surface but reduce BACE-mediated cleavage on the
basolateral side. First, on the way to the basolateral side APP
is cleaved by the competing -secretases, which consequently
reduces the amounts of APP available for BACE cleavage.
Second, because -secretory activity was only observed on the
basolateral side, the rather small amounts of APP, which are
targeted to the apical side, are an almost exclusive substrate
for BACE. Upon overexpression of BACE, very efficient -se-
cretory processing is observed at the expense of -secretory
processing. Under these conditions BACE appears to cleave
before -secretase. Thus it is likely that overexpressed BACE
has cleaved APP already before it reaches the trans-Golgi
network, the compartment known to be required for polarized
FIG. 6. Schematic representation of
the polarized sorting of APP, the
secretase activities, and their cleav-
age products. For details, see
“Discussion.”
Sorting of -Secretase Limits A Production5642










sorting in MDCK cells (41, 42). Consequently, the strongly
increased APPs undergoes unpolarized secretion. In contrast,
the membrane-bound cleavage products of BACE, the APP
CTFs, which are the immediate precursors for A generation,
still contain their cytoplasmic sorting signal and are conse-
quently targeted to the basolateral side where they can be
further processed to A (see above).
Finally, our data suggest that, at least in MDCK cells, APP
is not the major physiological substrate of BACE, because both
are targeted in the opposite direction. This is supported by the
observation that the -secretase activity in mice is unable to
efficiently cleave endogenous APP whereas human APP,
which has a slightly different amino acid sequence in its A
domain, is cleaved normally (43). Therefore, APP cannot be
the major BACE substrate in mice as well. Indeed, while this
report was under review, a novel BACE substrate was identi-
fied (44).
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